Nocion Therapeutics Secures $23M in Series B Extension Funding

Nocion Therapeutics, Inc. has been quietly doing what the best biotech companies do. Ignore the noise, listen to the neurons, and let the data talk back. Founded in 2018 in Watertown, Massachusetts, this team came out of the lab, not the hype cycle, with an idea that felt obvious only after it existed. Permanently charged sodium channel blockers that silence misfiring sensory neurons without muting the rest of the system. Not numbing the room, just telling the loudest heckler to take a seat.

This week, Nocion Therapeutics, Inc. added another $23 million to its Series B, led by Arkin Bio Capital and Monograph Capital, bringing the total Series B to $93 million and cumulative funding to $122 million. Existing investors like F-Prime Capital, Canaan Partners, Lumira Ventures, Mass General Brigham Ventures, BioInnovation Capital, Mission BioCapital, Osage University Partners, Morningside, and a strategic investor stayed in the pocket. That kind of follow-on support is not about vibes. It is about belief reinforced by execution.

Richard P. Batycky, Ph.D., President and CEO, has been here before. Civitas Therapeutics did not win by talking louder, it won by delivering Inbrija to patients with Parkinson's disease. James Ellis, Ph.D., Chief Scientific Officer, brings the kind of scientific discipline that comes from leading GSK’s Innovation Hub and standing in front of real data. Add scientific founders Bruce Bean, Clifford Woolf, and Bruce Levy, and you get a bench that knows exactly which signals matter and which ones are just noise.

The lead program, taplucainium, formerly NTX-1175 and NOC-110, is now deep into the ASPIRE Phase 2b trial for refractory and unexplained chronic cough. First patient dosed in November 2024. Enrollment expanding across the US, Canada, the United Kingdom, and Europe. Millions of patients cough every day with no good answers, especially after P2X3 antagonists fall short. Nocion’s approach goes downstream, entering only activated nociceptors through open channels and shutting down the pathological signal without flattening everything else. That distinction is the difference between precision and compromise.

The Series B extension stretches runway into 2027, funds completion of Phase 2b, and sets the table for Phase 3 readiness. It also sends a message. In a market that rewards patience and punishes shortcuts, selectively silencing the problem instead of the patient might be the smartest noise reduction strategy in the room.